CVR 25834844Public limited company (A/S)Fremstilling af andre fødevarer i.a.n. (108900)VejleFounded 2 Jan 2001
Employees
959
CVR registry, Aug 2026
+68 (+7.6%) over 12 months
Revenue
1.7B
DKK, annual report 2025
+51.8% on 2024
Result
-280.8M
DKK, annual report 2025
Equity
1.3B
DKK, annual report 2025
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about FERTIN PHARMA A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexAspeya Inc.100% of capital and votes, since 5 Feb 2026
Michael Henrik Thomsensince 1 Nov 2023
100% of capital and votessince 5 Feb 2026
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR 51452313100% of capital and votes19 Dec 2008 to 17 Jan 2017
CVR 38205072100% of capital and votes17 Jan 2017 to 5 Feb 2026
CVR records founders at incorporation. It does not record whether they are alive or still involved.
30 Aug 2010 to 2 Nov 2026.
22 Feb 2001 to 2 Nov 2026. Showing 25 of 42. The list above has every one.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 932,545 | 892,580 | 1,012,566 | 1,104,175 | 1,676,276 |
| Operating profit | +96,348 | -74,809 | -75,903 | -165,996 | -269,178 |
| Result for the year | +37,642 | -91,376 | -136,701 | -259,011 | -280,841 |
| Equity | 681,404 | 596,345 | 458,408 | 1,503,550 | 1,269,900 |
| Total assets | 2,021,489 | 2,249,475 | 2,498,199 | 2,570,785 | 3,607,057 |
| Employees (average) | 654 | 690 | 798 | 868 | 1,233 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | -5.9% | -4.3% | 13.4% | 9% | 20.3% |
| EBIT margin (overskudsgrad) | 10.3% | -8.4% | -7.5% | -15% | -16.1% |
| EBITDA | 240,703 | 54,203 | 45,039 | -9,267 | 56,146 |
| EBITDA margin | 25.8% | 6.1% | 4.5% | -0.8% | 3.4% |
| Employee growth (vækst i antal ansatte) | 5.1% | 5.5% | 15.7% | 8.8% | 4.3% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -36,428 | -25,960 | -5,124 | -7,508 | -99,730 |
| Gearing, NIBD / EBITDA | Net cash | Net cash | Net cash | n.m.note 1 | Net cash |
| ROIC (afkast af investeret kapital) | 6.7% | -9.6%note 2 | -11.6%note 2 | -13.3%note 2 | -15.7%note 2 |
| Capex (investeringer i anlægsaktiver) | 188,412 | 218,761note 3 | 214,532note 3 | 177,937note 3 | 301,461 |
| Capex % of sales (investeringer i procent af omsætningen) | 20.2% | 24.5%note 3 | 21.2%note 3 | 16.1%note 3 | 18% |
| FCFF / EBITDA (pengestrømskonvertering) | 0.4% | Not reported | Not reported | Not reported | -546.8%note 4 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | 858,403 | 1,034,060 | 1,280,664 | 291,101 | 1,638,071 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. Group figures (koncern).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 3 Jul 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 19 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 11 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 30 Jun 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 29 Jun 2022
FERTIN PHARMA A/S has new leadership, a good time to reach out.
Signal, a Dandex estimate. Lapses 9 Jan 2027.
6 registered in CVR.
P-number 1008193947Dandyvej 19, 7100 Vejle
P-number 1013082568Industrivej 8, 7120 Vejle Øst
P-number 1009345589Fertinvej 5, 7100 Vejle
P-number 1015219846Dandyvej 1, 7100 Vejle
P-number 1009345597Struergade 22, 2630 Taastrup
P-number 1022922757Industrivej 2, 7120 Vejle Øst
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.
